Home

Nivolumab gastric cancer FDA approval

FDA Approves First Immunotherapy for Initial Treatment of

April 16, 2021 Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or.. On May 20, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with completely resected esophageal or gastroesophageal junction (GEJ).. Research News FDA Approves Nivolumab Plus Chemo for Frontline Advanced Gastric Cancer The FDA approved the first immunotherapy for the first-line treatment of advanced gastric cancer, Bristol Myers Squibb's Opdivo in combination with chemotherapy See full prescribing information for OPDIVO. patients with advanced or metastatic gastric cancer, gastroesophageal OPDIVO (nivolumab) injection, for intravenous use junction cancer, and esophageal..

FDA approves nivolumab for resected esophageal or GEJ cance

Gastric Cancer Foundation FDA Approves Nivolumab Plus

CheckMate 649: Nivolumab plus chemotherapy for gastric and

On August 16, 2018, the Food and Drug Administration granted accelerated approval to nivolumab (Opdivo, Bristol-Myers Squibb Company Inc.) for patients with metastatic small cell lung cancer (SCLC).. Officials with the FDA have approved nivolumab (Opdivo, Bristol Myers Squibb) in combination with chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, regardless of programmed death-ligand 1 (PD-L1). According to a press release, nivolumab is the. On September 22, 2017, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for patients with recurrent locally advanced or metastatic,.. Some patients diagnosed with advanced stomach (gastric) cancer may live longer if they are treated with the immunotherapy drug nivolumab (Opdivo) plus chemotherapy as an initial treatment, according to results from a large clinical trial

The FDA approved nivolumab (OPDIVO) in combination with chemotherapy as a first-line treatment for advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma.. This approval makes nivolumab the first approved immunotherapy for first-line treatment of gastric cancer, the FDA noted. In a press release announcing the approval, Richard Pazdur, MD. OPDIVO (nivolumab) injection, for intravenous use •patients with advanced or metastatic gastric cancer, gastroesophageal Initial U.S. Approval: 2014 junction cancer, and esophageal adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.1 2

The FDA approved nivolumab (Opdivo) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma. This is the first frontline immunotherapy regimen approved for gastric cancer. Today's approval is the first treatment in. Nivolumab inhibits PD-1, a protein that blocks the immune system from attacking cancer cells. It is the first first-line immunotherapy treatment to receive approval in the U.S. for patients with gastric cancer, which affects about 28,000 individuals each year. The five-year survival rate for metastatic disease is 5%. The approval came after a. Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma •patients with advanced or metastatic gastric cancer, gastroesophageal cancer, and esophageal adenocarcinoma in combination with fluoropyrimidine -and platinumcontaining chemotherapy. (1.1 2) a . This indication is approved under accelerated approval based on overal

The FDA has approved nivolumab (Opdivo) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine. The FDA has approved Opdivo (nivolumab) plus chemotherapy for the first-line treatment of patients with gastric cancer. is the first treatment in more than a decade to show a survival benefit. In April 2021, the paradigm shifted when the FDA approved nivolumab (Opdivo) for use in combination with select types of chemotherapy in the frontline treatment of patients with advanced or..

  1. Nivolumab (Opdivo; Bristol Myers Squibb) is an immunotherapy that is FDA approved for 11 cancer indications, 1 with the most recent approval for use in combination with certain chemotherapy for the initial treatment of gastric cancer. 2 This latest action marks an important milestone as the first FDA-approved immunotherapy for first-line treatment of gastric cancer.
  2. istration (FDA) has accepted a priority review for Bristol Myers Squibb's (BMS) Opdivo (nivolumab) plus chemotherapy combination in stomach cancer. The US regulator will review the combo treatment for the first-line treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer.
  3. istration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
  4. istration has approved Bristol-Myers Squibb Co.'s Opdivo (nivolumab), in combination with certain types of chemotherapy, to become.

The FDA has granted approval to nivolumab (Opdivo ®, Bristol-Myers Squibb Company) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the initial treatment of patients with advanced/metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Standard first-line chemotherapy options for advanced or metastatic human epidermal growth. FDA approves immunotherapy for first-line treatment of advanced gastric cancer. Download PDF Copy. Reviewed by Emily Henderson, B.Sc. Apr 16 2021. Today, the U.S. Food and Drug Administration. The FDA announced today that it approved Opdivo (nivolumab) in combination with chemotherapy to treat gastric cancer, among other diseases. Opdivo, developed by Bristol-Myers Squibb, when used in combination with certain types of chemotherapy is designed to treat advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma

Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer. Bristol Myers Squibb BMY announced that its blockbuster immuno-oncology drug, Opdivo (nivolumab), has been approved for another. SILVER SPRING, Md., April 16, 2021 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment.

The FDA has approved Bristol-Myers Squibb's (NYSE: BMY) Opdivo (nivolumab)as a first-line therapy for advanced or metastatic gastric cancer. The approval is the first immunotherapy approved for. The FDA based the approval in part on results of a randomized trial that included 1,581 patients with previously untreated advanced or metastatic gastric cancer, gastroesophageal junction cancer. The FDA-approved dosing for Opdivo (injection for intravenous use) for patients with gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma is 360 mg every three weeks (30. FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction. The U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of.

FDA Approves Nivolumab Plus Chemotherapy as 1L Therapy for

  1. The FDA has set a Prescription Drug User Fee Act action date of May 25, 2021, for this potential approval. Today's filing acceptance by the FDA marks important progress for the gastrointestinal cancer community and builds on our momentum of advancing immunotherapies to help improve the lives of those with advanced gastric and esophageal tumors, said Ian M. Waxman, MD, development lead.
  2. ed by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations
  3. The FDA granted priority review to nivolumab for two gastrointestinal cancer indications, according to the agent's manufacturer.One designation applies to use of the agent with fluoropyrimidine.
  4. istration (FDA) recently approved Bristol Myers Squibb's Opdivo for the initial treatment of certain types of cancer. Opdivo, the trade name for the generic Nivolumab, can now be used in combination with certain types of chemotherapy for initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma
  5. istration (FDA) increased the number of types of cancer for which immunotherapeutics known as checkpoint inhibitors are a treatment option when it expanded the approved uses of nivolumab (Opdivo) and pembrolizumab (Keytruda) to include certain patients with liver cancer and stomach cancer, respectively.. These two decisions mean that there is now at least.

April 21, 2021. On April 16, the U.S. Food and Drug Administration (FDA) approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for frontline treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: On April 16, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma

The FDA approved nivolumab (Opdivo, Bristol Myers Squibb), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma The FDA approved nivolumab (Opdivo) in combination with certain types of chemotherapy for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction.

16Apr2021 FDA Approves Opdico/Nivo +Chemotherapy as First Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma ahead of 25May2021 PDUFA date 22Apr2021 CHMP Positive Opinion for Opdivo/Nivo+Yervoy/Ipi as First Line Treatment for Unsectable Malignant Pleural Mesotheliom In 2019, the drug pembrolizumab (Keytruda) was approved for the treatment of some patients with advanced esophageal cancer. The following year, researchers reported that using nivolumab plus chemotherapy as an initial treatment for advanced stomach cancer improved overall survival. That study, CheckMate 649, included patients with esophageal. The Food and Drug Administration (FDA) has approved the combination of Opdivo (nivolumab) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma, making it the first front-line immunotherapy agent approved in the gastric cancer space The FDA is committed to bringing new safe and effective treatment options like nivolumab to patients with advanced cancer. Today, @US_FDA approved nivolumab, in combination with chemotherapy for 1L treatment of patients with metastatic gastric/GE junction/esophageal adenocarcinoma: 1st FDA-approved immunotherapy for the 1L treatment of.

The FDA approved nivolumab (Opdivo) plus chemotherapy as the first immunotherapy-containing regimen for previously untreated advanced/metastatic gastric or esophageal cancer.. The approval. FDA approves nivolumab for resected oesophageal or GEJ cancer 21 May 2021 On May 20, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with completely resected oesophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received neoadjuvant. The Food and Drug Administration grants accelerated approval to Merck's Keytruda (pembrolizumab), the checkpoint inhibitor drug for HER2-positive gastric cancer. 1 Keytruda, the anti-PD-1 therapy was approved in combination with trastuzumab (Herceptin - a monoclonal antibody), fluoropyrimidine- and platinum-based chemotherapy as first-line treatment for adult patients with locally advanced. The approval comes after the agent received Priority Review and Orphan Drug designations for this indication. There are approximately 28,000 new diagnoses of gastric cancer annually in the US and. U.S. Food and Drug Administration assigned a target action date of May 25, 2021 Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo ® (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with advanced or.

The FDA granted approval to adjuvant nivolumab (Opdivo) for the treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT), according to a press release from Bristol Myers Squibb, developer of the agent. 1. The agent was. FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer. SILVER SPRING, Md., April 16, 2021 /PRNewswire/ --Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab. The accelerated approval indication for pembrolizumab (Keytruda) in patients with gastric cancer in the third-line setting will be voluntarily withdrawn by Merck, the pharmaceutical company responsible for the agent, according to a press release. 1 The accelerated approval was aimed towards patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ. The FDA will reassess 6 indications for immune checkpoint inhibitors that were granted accelerated approval but failed to prove clinical benefit in confirmatory trials in a public meeting of the. Adjuvant Nivolumab in Esophageal Cancer Adjuvant chemotherapy has not improved disease-free survival among patients with resected esophageal or gastroesophageal junction cancer. In this trial, afte..

The U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced gastric cancer in April 2021. There are approximately 28,000 individuals diagnosed with gastric cancer each year in the U.S determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. (1.2, 2.1) Small Cell Lung Cancer (SCLC

The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer. Please note that following on from information received from the company the timelines for this appraisal have been revised The introduction of immunotherapy to the treatment paradigms of esophageal and gastric cancers has been an exciting advance, said Namrata (Neena) Vijayvergia, MD, who added that although agents, such as nivolumab (Opdivo), are not yet approved by the FDA in the adjuvant or metastatic settings, they should be considered for use based on National Comprehensive Cancer Network (NCCN) recommendations

FDA Approves Opdivo (nivolumab) in Combination with

Appreciate the recent FDA approval of nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for patients with previously untreated locally advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma On April 16, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo ®) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma

FDA Approves Nivolumab Plus Chemo for - Cancer Networ

Opdivo is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer. The Food and Drug Administration has given its stamp of approval to Bristol-Myers Squibb for a new. Gastric cancer, also known as stomach cancer, is the fifth most common cancer and the third leading cause of cancer death worldwide, with over 1,000,000 new cases and approximately 770,000 deaths. The immune checkpoint inhibitor Opdivo () may be a safe and effective treatment for people with advanced gastric or esophagogastric junction cancer who failed standard chemotherapy regimens, results from a Phase 3 clinical trial suggest. A three-year survival analysis of the trial, called ATTRACTION-2 (NCT02267343), showed that the treatment significantly extended patients' lives and the. OPDIVO ® (nivolumab) is a prescription medicine that may be used to help prevent cancer of the tube that connects your throat to your stomach (esophageal cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer) from coming back after it has been treated with chemoradiation followed by surgery to remove the cancer, but some cancer cells were still present in. FDA Approves Nivolumab in Combination with Chemotherapy for Metastatic Gastric Cancer and Oesophageal Adenocarcinoma. On 16 April 2021, the US Food and Drug Administration (FDA) approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric.

FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and oesophageal adenocarcinoma 19 Apr 2021 the Food and Drug Administration approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and. On April 16, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo ®) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma

FDA Approves Nivolumab Plus Chemo for Frontline Gastric Cance

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy. The U.S. Food and Drug Administration has approved first immunotherapy for the first-line treatment of gastric cancer. Opdivo (nivolumab), in combination with certain types of chemotherapy has been approved for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma

Endoscopic Case of Ulcerated Gastric Cancer - YouTube

Opdivo (nivolumab) FDA Approval History - Drugs

  1. istration (FDA) for stomach (gastric) cancer. The list includes generic and brand names. This page also lists common drug combinations used in stomach (gastric) cancer. The individual drugs in the combinations are FDA-approved
  2. The drug has been approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal.
  3. The panel voted against maintaining a gastric cancer indication for pembrolizumab (Keytruda, Merck) and a hepatocellular carcinoma indication for nivolumab (Opdivo, Bristol Myers Squibb). Data.
  4. istration's (FDA's) Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing two of six accelerated approvals of cancer treatments that it reevaluated in a recent meeting, citing the failure to verify benefit in follow-up trials.. The committee voted 6-2 to withdraw the accelerated approval of pembrolizumab for the treatment of patients with recurrent.
  5. The FDA has approved nivolumab in combination with certain chemotherapies for the initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. The FDA has approved nivolumab (Opdivo) in combination with certain chemotherapies for the initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer,..
  6. The drug called Nivolumab or Opdivo is an immunotherapy-based drug and can be used in combination with the other chemotherapeutic drugs to control the cancer of stomach. Patients who suffer from the advanced form of metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma can be put on Nivolumab to cure the disease
  7. On April 16, 2021, the FDA approved the PD-1 inhibitor nivolumab (Opdivo; Bristol Myers Squibb), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal adenocarcinoma.Nivolumab was the first immunotherapy approved by the FDA for first.
Bristol-Myers Squibbâ s Opdivo Receives US FDA Approval

FDA Agrees to Priority Review of Opdivo for Gastric

  1. istration's (FDA) Oncologic Drugs Advisory Committee did not agree in a recent meeting to maintain the accelerated approval of Bristol Myers Squibb's Opdivo (nivolumab) as a second-line treatment of hepatocellular carcinoma. Five Committee members voted against the accelerated approval, while four voted to maintain the approval
  2. Recent breakthrough results from immune checkpoint inhibitors (ICI) have paved the way to a new era of cancer immunotherapy. In particular, inhibition of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis with ICI including nivolumab and pembrolizumab has been emerging as a novel treatment strategy for advanced gastric cancers (GC)
  3. FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status - April 16, 202
  4. In terms of immunotherapy for gastric cancer, in mid-April this year, Bristol-Myers Squibb's (BMS) anti-PD-1 therapy Opdivo (Odivo, generic name: nivolumab, nivolumab) was approved by the US FDA, combined with fluoropyrimidine and platinum Class-like combination chemotherapy, first-line treatment of advanced or metastatic gastric cancer (GC.
Immune Cell Infiltration | InSphero

FDA Approves Nivolumab, First Immunotherapy for First-line

Apr. 19, 2021, 06:35 AM. (RTTNews) - The U.S. Food and Drug Administration has approved Bristol-Myers Squibb Co.'s Opdivo (nivolumab), in combination with certain types of chemotherapy, to become. The FDA approved Opdivo® (nivolumab) for melanoma patients. Opdivo, made by Bristol-Myers Squibb (BMS), belongs to a class of immunotherapies called checkpoint inhibitors. BMS's Opdivo is the second FDA-approved checkpoint inhibitor targeted at an immune protein called PD-1 Recently (April 16), FDA approved PD-1 nivolumab (opdivo) of BMS, Bristol-Myers Squibb Co.) for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma in combination with first-line chemotherapy, which caused a great sensation in the tumor circle 4. Bristol Myers Squibb statement on Opdivo (nivolumab) small cell lung cancer US indication. News release. Bristol Myers Squibb. December 29, 2020. Accessed March 22, 2021. https://bit.ly/2X5PVFK . 5. FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer. FDA. Updated August 20, 2018

Bristol Myers Squibb (BMY) Stock Message Board - InvestorsHubAdenocarcinoma of the Esophagus Presenting as OrbitalImmune Checkpoint Inhibitors Are Boosting the Cancer Battle

Just weeks before the meeting, on April 16, the FDA approved nivolumab plus chemotherapy as a first-line treatment for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and. The drug received FDA approval in January 2021 for use in adult patients with locally advanced or Considerations for Adjuvant Nivolumab in Esophageal or GEJ Cancer . In the phase 3 Tabernero J, Prokharau A, et al. Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone. FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer. SILVER SPRING, Md., April 16, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab. This approval of pembrolizumab is the first time that the FDA has approved a cancer treatment for an indication based on a common biomarker rather than the primary site of origin. ©2019 American Association for Cancer Research. MeSH terms Antibodies, Monoclonal, Humanized / administration & dosage. Nivolumab (Opdivo) as adjuvant therapy following complete resection of esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who previously received neoadjuvant chemoradiotherapy was approved by the FDA, according to the company responsible for developing the drug, Bristol Myers Squibb. 1 The supplemental biologics license application for this indication. The US FDA has approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer